{"id":"ly3537982","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GLP-1 receptor agonists enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety through central nervous system effects. LY3537982 is being developed as a next-generation GLP-1 agonist, potentially with improved pharmacokinetic properties or dual/triple agonist activity targeting GLP-1 and other metabolic receptors.","oneSentence":"LY3537982 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:54.316Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT06119581","phase":"PHASE3","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-12-21","conditions":"Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis","enrollment":1264},{"nctId":"NCT06890598","phase":"PHASE3","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":700},{"nctId":"NCT07439250","phase":"PHASE1","title":"A Study of Olomorasib (LY3537982) in Healthy Participants","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-03-02","conditions":"Healthy","enrollment":15},{"nctId":"NCT07227025","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-03-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":60},{"nctId":"NCT07137689","phase":"PHASE1","title":"A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-08-18","conditions":"Renal Insufficiency","enrollment":32},{"nctId":"NCT07124013","phase":"PHASE1","title":"A Study of Olomorasib (LY3537982) in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2025-09-16","conditions":"Healthy","enrollment":191},{"nctId":"NCT07044271","phase":"PHASE1","title":"A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-07-11","conditions":"Healthy","enrollment":120},{"nctId":"NCT04956640","phase":"PHASE1, PHASE2","title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-07-19","conditions":"Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms","enrollment":540},{"nctId":"NCT06719128","phase":"PHASE1","title":"A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-12-06","conditions":"Hepatic Insufficiency, Healthy","enrollment":46},{"nctId":"NCT06235983","phase":"PHASE1","title":"A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-02-29","conditions":"Advanced Solid Tumors","enrollment":12},{"nctId":"NCT05901311","phase":"PHASE1","title":"A Study of [14C]-LY3537982 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-06-05","conditions":"Healthy","enrollment":16},{"nctId":"NCT05860933","phase":"PHASE1","title":"A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-05-08","conditions":"Healthy","enrollment":30},{"nctId":"NCT06111521","phase":"PHASE1","title":"A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-10-27","conditions":"Healthy","enrollment":35},{"nctId":"NCT05824858","phase":"PHASE1","title":"A Study of the Effect of Food on LY3537982 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-04-12","conditions":"Healthy","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Olomorasib"],"phase":"phase_3","status":"active","brandName":"LY3537982","genericName":"LY3537982","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY3537982 is a GLP-1 receptor agonist that activates the glucagon-like peptide-1 receptor to improve glycemic control and promote weight loss. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}